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a  b  s  t  r  a  c  t
Bluetongue  virus  (BTV)  infections  in ruminants  pose  a permanent  agricultural  threat  since  new  serotypes
are  constantly  emerging  in new  locations.  Clinical  disease  is  mainly  observed  in sheep,  but cattle  were
unusually  affected  during  an  outbreak  of BTV  seroype  8 (BTV-8)  in  Europe.  We  previously  developed  an
experimental  vaccine  based  on  recombinant  viral  protein  2 (VP2)  of  BTV-8  and  non-structural  proteins
1 (NS1)  and  NS2  of  BTV-2,  mixed  with  an  immunostimulating  complex  (ISCOM)–matrix  adjuvant.  We
demonstrated  that  bovine  immune  responses  induced  by this  vaccine  were  as  good or superior  to  those
induced by  a classic  commercial  inactivated  vaccine.  In  this study,  we  evaluated  the  protective  efﬁcacy  of
the  experimental  vaccine  in  cattle  and,  based  on  the  detection  of VP7  antibodies,  assessed  its  DIVA  compli-
ancy following  virus  challenge.  Two  groups  of  BTV-seronegative  calves  were  subcutaneously  immunized
twice  at a 3-week  interval  with  the  subunit  vaccine  (n  =  6)  or with  adjuvant  alone  (n = 6).  Following  BTV-
8  challenge  3 weeks  after  second  immunization,  controls  developed  viremia  and  fever  associated  with
other  mild  clinical  signs  of bluetongue  disease,  whereas  vaccinated  animals  were  clinically  and  virologi-
cally  protected.  The  vaccine-induced  protection  was  likely  mediated  by  high  virus-neutralizing  antibody
titers  directed  against  VP2  and  perhaps  by  cellular  responses  to  NS1  and  NS2.  T lymphocyte  responses
were  cross-reactive  between  BTV-2  and  BTV-8,  suggesting  that  NS1  and NS2  may  provide  the  basis  of an
adaptable  vaccine  that  can be  varied  by using  VP2  of  different  serotypes.  The  detection  of  different  levels
of  VP7  antibodies  in  vaccinated  animals  and  controls  after  challenge  suggested  a  compliancy  between
the  vaccine  and  the  DIVA  companion  test.  This  BTV  subunit  vaccine  is a  promising  candidate  that  should
be  further  evaluated  and  developed  to protect  against  different  serotypes.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Bluetongue virus (BTV) is the causative agent of the primarily
ector-borne hemorrhagic bluetongue (BT) disease of ruminants.
ince 1998 at least 8 of 26 serotypes have been detected within the
uropean Union [1] and the introduction of new BTV serotypes is a
ermanent threat to the region. Typically, BT disease most severely
∗ Corresponding author at: National Veterinary Institute, Department of Virology,
mmunology, and Parasitology, Ulls väg 2B, Uppsala, Sweden. Tel.: +4618 67 4407.
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
clinically affects sheep [2]. However, the 2006 BTV-8 outbreak in
central and northern Europe caused clinical signs in cattle includ-
ing abortion and teratogenic effects [3,4]. The vaccination of cattle,
BTV’s main amplifying host, along with small ruminants, is impor-
tant to decrease virus spread [5].
Although modiﬁed live virus (MLVs) and inactivated vaccines
have been suggested to be effective in controlling BTV in Europe
[6–8], MLVs are sometimes associated with viremia, clinical dis-
ease, and risk of gene segment reassortment [9–11], while safer
inactivated vaccines presently cost more [8] or may be difﬁcult
to produce since some serotypes may not replicate well in vitro
[12]. Neither vaccine type currently allows the differentiation of
infected from vaccinated animals (DIVA) nor is easily adaptable to
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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arget multiple BTV serotypes. The use of DIVA-compliant vaccines
ould potentially help countries quickly return to BTV-free sta-
us [13], and enable surveillance of BTV epidemiology and vaccine
fﬁcacy. Vaccine adaptability to novel or multiple BTV serotypes
s increasingly necessary given the recent co-circulation of differ-
nt serotypes within Europe [14]. Many experimental BTV vaccines
im to possess these important qualities, while being as safe and
ffective as current vaccines (reviewed by [15]).
Vaccine-induced protection against BTV is largely attributed
o serotype-speciﬁc virus-neutralizing antibodies induced by viral
rotein 2 (VP2) [16–19]. The virus’s non-structural (NS) proteins
nduce cell-mediated immune responses that may  also play a
rotective role [20–23]. We  previously designed and optimized
 recombinant subunit vaccine against BTV-8 composed of VP2
rom BTV-8 and NS1 and NS2 from BTV-2, with a VP7-based
IVA characteristic [24] that can potentially be used to detect
ntibodies in samples from animals infected with any serotype
25]. We  determined that, in cattle, this vaccine induced strong
eutralizing antibody titers, VP2-, NS1-, and NS2-speciﬁc anti-
odies, and cellular immune responses to NS1 [26] that may
ontribute to a successful multi-serotype vaccine [27]. Here, we
imed to evaluate the clinical and virological protective efﬁcacy
f the experimental vaccine against virulent BTV-8 challenge in
attle and to verify its DIVA compliancy using existing diagnostic
ssays.
. Materials and methods
.1. Vaccine production
Recombinant VP2 of BTV-8 and NS1 and NS2 of BTV-2 were
roduced and puriﬁed as described previously [26]. Each 2.5 ml
ubunit vaccine (SubV) dose contained 150 g each of puriﬁed VP2,
S1, and NS2 and 450 g AbISCO®-300 (Isconova AB, Sweden), an
mmunostimulating complex (ISCOM)-based adjuvant.
.2. Challenge virus
To induce both a viremia and clinical signs associated to BTV,
he challenge virus consisted of two viral cell suspensions of BTV-8
train isolated from a BTV-8-viremic cow during a 2007 outbreak in
rance, on (i) embryonated chicken eggs (ECE) and passaged twice
n baby hamster kidney (BHK-21) cells (BHK suspension; 6 × 106
f 50% tissue culture infective dose (TCID50)/ml, or (ii) Culicoides-
erived (KC) cells (kindly provided by the Pirbright Institute, UK)
ollowed by one passage on the same cell line for virus ampliﬁca-
ion (KC suspension). The KC suspension was analyzed by RT-qPCR
AdiavetTM BTV Realtime ADI352, Adiagene, France) and resulted
n a Ct value of 14.1.
.3. Animals, experimental design, clinical examinations, and
ampling
Twelve conventionally reared female Holstein calves aged 6–12
onths were housed in the Biosecurity Level 3 animal facilities of
he National Institute of Agricultural Research (INRA) Research Cen-
er (Nouzilly, France). The calves originated from the same BVDV-
nd BHV1-free herd, were seronegative for BTV antibodies, and
ere not previously vaccinated against BTV. Animals were divided
andomly into two groups (n = 6) and housed in the same room,
eparated by a fence. All procedures were approved by the ethical
eview board of Val de Loire (CEEA VdL, committee number n◦19,
le number 2012-08-01).
Animals were immunized subcutaneously on the left side of the
eck at a 3-week interval with SubV or with 450 g AbISCO®-300
n PBS (Control). Three weeks after second vaccination all animals2 (2014) 6614–6621 6615
were subcutaneously inoculated with 2.5 ml  each of BTV-8 prepara-
tions on the right (BHK suspension) and left (KC suspension) sides of
the neck (post-infection day 0 (PID0)). Clinical examinations were
performed as shown in Fig. 1, and clinical scoring performed as
described previously [28]. Samples for antibody, viremia, and lym-
phocyte proliferation analyses were collected as indicated in Fig. 1,
in dry, ethylene diamintetraacetic acid (EDTA), and heparinized
tubes (BD Biosciences, USA), respectively.
2.4. Virus detection by RT-qPCR and ECE inoculation
Viral RNA was  extracted using a Magnatrix robot and a pan-
BTV qPCR based on segment 1 (VP1) of BTV [29] was performed.
The standard curve was obtained by dilution of a viral suspension
(105.9 TCID50 equivalent units/ml), as performed previously [30].
The quantity of viral RNA is expressed in log10 TCID50 equivalent
units/ml.
ECE inoculation was  performed as described previously [31], in
ﬁve 12-day-old embryonated speciﬁc pathogen-free chicken eggs
(Håtunaholm, Sweden) per calf blood sample collected on PID8.
Dead embryos were scored as positive if they showed hemorrhages
characteristic of BTV infection. Embryos were homogenized after
death or on day 7, after placement at +4 ◦C for at least 4 h. RNA
was extracted from swabs of homogenized embryos and RT-qPCR
performed as described above.
2.5. BTV-speciﬁc antibody detection
Virus neutralizing assays were performed in duplicate on Vero
cells, using serially diluted sera from 1:2 to 1:256 (as described
previously [32]). BTV-speciﬁc CPE were identiﬁed under a light
microscope after 5 days of incubation. The neutralizing titer
was deﬁned as the highest dilution allowing neutralization of
100 TCID50 of BTV-8.
Competitive (c) enzyme-linked immunosorbent assays (ELISAs)
were used to measure speciﬁc serum antibodies to VP2 of BTV-8 and
VP7 of any BTV serotype (ID Screen® Bluetongue Serotype 8 Com-
petition and ID Screen® Bluetongue Competition, ID Vet, France,
respectively), according to the manufacturer’s protocols. Results
are expressed as 100% minus competition percentage (100 times
[ODsample/ODnegative control]).
Antibodies speciﬁc to NS1 and NS2 (BTV-2) were ana-
lyzed using indirect ELISAs as described previously [26]. Results
are expressed as log10-transformed antibody titers, which
were calculated by linear regression to the corrected OD
(COD = ODprotein − ODbackground control) value of negative control sera
at a dilution factor of 10. For calculating means and performing sta-
tistical analysis, values under the detection threshold were set to
that threshold (dilution factor 10).
2.6. BTV-speciﬁc lymphocyte proliferation assays
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized blood of animals as previously described [33], then
stored in liquid nitrogen. Cells were restimulated, in duplicate,
as described previously [34], with 0.03–1 g individual proteins
(VP2, NS1, NS2) or 103.9 TCID50/well of UV-inactivated BTV-8 and
relevant background controls (Sf9 cell lysate for VP2, NS1; non-
transfected BL21-AITM E. coli lysate for NS2; uninfected Vero cell
lysate for virus). Absorbances were measured 7–16 h after addition
of alamarBlue®-reagent (Invitrogen, UK), at 570 nm and 595 nm.
OD (OD570nm − OD595nm) and COD values were calculated for all
protein- and virus-speciﬁc stimulations.
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Fig. 1. Timeline of the study. Twelve calves were immunized twice at a 3-week interval with an experimental subunit vaccine against BTV-8 (SubV, n = 6) or adjuvant alone
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contrast, BTV RNA was  detected in blood of 1/6 controls on PID2,
2/6 controls on PID4, and in all controls on PID6–25 (experiment
Fig. 2. Kinetics of clinical scores and rectal temperatures of calves following chal-
lenge with BTV-8. Animals were vaccinated with SubV (white diamonds) or ControlControl, n = 6) (black arrows), then challenged with BTV-8 three weeks after the se
etection and whole blood for virus detection, and isolation of peripheral blood mon
y  black dots at the indicated week or post-infection day (PID).
.7. Statistical analyses
According to the sample data distribution, analysis among two
roups or time points and three or more time points was  per-
ormed using non-parametric Mann–Whitney and Kruskal–Wallis
ests for independent groups, respectively, in R [35], or using Stu-
ent’s t-tests in Excel. Statistical signiﬁcance was set to p ≤ 0.05 (*)
r p ≤ 0.01 (**). Where applicable, values are provided as mean ± SD.
. Results
.1. Clinical observations
.1.1. Local and general reactions following vaccination
Mild (<3 cm)  localized injection site swellings were observed in
/6 SubV-immunized calves and in 1/6 controls and lasted 3 days
fter ﬁrst vaccination. Following second immunization, mild or
ild-to-moderate (<10 cm)  injection site swellings were observed
n 4/6 controls and in all vaccinated calves, respectively. Slightly
levated rectal temperatures were observed in both groups for
 days after both immunizations (maximum rectal temperatures
ean, SubV: 39.4 ± 0.3 ◦C; Control: 39.3 ± 0.4 ◦C) but the groups did
ot differ signiﬁcantly (p = 0.61).
.1.2. Clinical signs following BTV-8 challenge
Control calves showed slight general depression with appetite
oss (6/6, PID3–4), stiffness (4/6, PID7–8), and lameness (3/6,
ID4–6), and had a biphasic rectal temperature pattern that peaked
n PID4 and PID7 and reached over 40 ◦C in 1/6 and 2/6 ani-
als, respectively (PID4 range: 39.1–40.5 ◦C, mean: 39.6 ◦C; PID7
ange: 38.9–40.3 ◦C, mean: 39.7 ◦C). Other clinical signs of BTV
nfection were observed from PID2–14, including nasal discharge
4/6, PID5–6), congestion with slight edema of the nasal mucosa
2/6, PID5), and moderate edema in the intermandibular space (1/6,
ID5–6). Enlargement of right and left prescapular lymph nodes
as observed in all controls (PID5–14). The mean clinical scores
eaked between PID5–7 and remained elevated through PID14,
fter which no clinical examinations were performed until PID21
Fig. 2A).
In contrast to controls, SubV-vaccinated animals showed no sig-
iﬁcant increase in rectal temperature following challenge (range:
8.4–39.2 ◦C, p = 0.29; Fig. 2B) and 3/6 vaccinated calves demon-
trated no clinical signs throughout the study. In the remaining
hree SubV-vaccinated calves, very slight clinical signs were
bserved, including slight nasal discharge on PID5 (1/6) and stiff
alking in two animals on PID4 (1/6) and PID5 (1/6). Mean clinicalcores for vaccinated animals never exceeded 0.5 (PID5) and oth-
rwise remained at 0. Clinical scores of controls were signiﬁcantly
igher (p ≤ 0.05 or p ≤ 0.01) than those of vaccinated calves on each
ay from PID4–14 (Fig. 2A).vaccination (white arrow). Clinical examinations, collection of serum for antibody
lear cells (PBMCs) for lymphocyte proliferation assays were performed as indicated
3.2. Quantiﬁcation of viral RNA in blood and virus isolation in ECE
Using RT-qPCR analysis, no BTV RNA was  detected in blood col-
lected from vaccinated calves between PID0 and PID25 (Fig. 3A). In(black squares), challenged with BTV-8 (white arrow), and clinical examinations
were performed as indicated in Fig. 1. Clinical scores (A) and rectal temperatures
(B) are presented as group means. Standard deviations are indicated by upward
deﬂection lines and statistical signiﬁcance between groups is indicated by asterisks
(p  ≤ 0.05 [*] or p ≤ 0.01 [**]).
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Fig. 3. Detection of BTV RNA in whole blood of immunized calves after challenge with BTV-8. Calves were vaccinated with SubV (white diamonds) or Control (black
squares), then challenged with BTV-8 (white arrow), as indicated in Fig. 1. The quantity of viral RNA detected by RT-qPCR analysis is indicated as group means expressed
as  log10 TCID50 equivalent units/ml, with standard deviations indicated as upward deﬂection lines (A). Embryonated chicken eggs were inoculated, in quintuplicates, with
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ndicated (B). BTV RT-qPCR was performed on swabs from homogenized embryos 
espectively (B).
ermination). Peak viremic levels were observed on PID10 (mean:
.26 ± 0.44 log10 TCID50 equivalent units/ml).
These data were conﬁrmed by ECE inoculation of blood. Virus
as detected by induction of embryonic mortality between 2 and
 days post-inoculation in 2–5 of 5 inoculated eggs per calf blood
ample collected on PID8 from controls (Fig. 3B). The embryo mor-
ality and observed hemorrhagic characteristics were attributed to
TV since BTV RNA was detected only in swabs from homogenized
mbryos that had been inoculated with blood from controls. In con-
rast, no dead or hemorhaggic embryos were observed following
noculation with blood from vaccinated calves and no BTV RNA was
etected in these embryos (Fig. 3B).
ig. 4. Kinetics of BTV-8-neutralizing antibodies and protein-speciﬁc serum antibodies a
black  arrows) with SubV (white diamonds) or Control (black squares) and challenged 
irected against BTV-8 (A) were calculated using the Reed–Muench method and are exp
nd  expressed as 100% minus the competition percentage (100 times ODsample/ODnegative
ndirect ELISAs and are expressed as log10 antibody titers. Upward deﬂection lines indica
*]  or p ≤ 0.01 [**]). lesions after 1 week of incubation, and the number of eggs with embryo lesions
sitive (27 < Ct < 38) and negative samples (no Ct value) are indicated by (+) or (−),
3.3. Detection of neutralizing and protein-speciﬁc antibodies
BTV-8-speciﬁc neutralizing antibodies were detected in the
sera of 5/6 vaccinated calves 1 week after second vaccination and
in all vaccinated calves 2 weeks later (mean: 4.5 ± 1.4 log2 titers)
(Fig. 4A). These titers remained high 3 weeks after challenge. In
contrast, BTV-8 neutralizing antibodies were only detected in the
sera of controls after challenge.BTV-8 VP2-speciﬁc serum antibodies were detected by ELISA
in all vaccinated calves 1 week after second immunization, con-
tinued to increase through 1 week after challenge, and remained
stable 2 weeks later (Fig. 4B). VP2-speciﬁc antibodies were detected
gainst VP2 of BTV-8 and NS1 and NS2 of BTV-2 in calves. Calves were immunized
with BTV-8 (white arrow), as indicated in Fig. 1. Titers of neutralizing antibodies
ressed as log2 values. VP2-speciﬁc antibodies were detected by competitive ELISA
), (B) while antibodies directed against NS1 (C) and NS2 (D) were detected using
te standard deviations and statistical signiﬁcance is indicated by asterisks (p ≤ 0.05
6618 J. Anderson et al. / Vaccine 3
Fig. 5. Speciﬁc lymphocyte proliferation following NS1 (BTV-2), NS2 (BTV-2) and
UV-inactivated BTV-8 restimulation of isolated PBMCs from calves. Animals were
vaccinated with SubV (white bars) or Control (black bars) and challenged with BTV-
8  as indicated in Fig. 1. PBMCs were isolated from whole blood of calves 3 weeks
after second vaccination and restimulated against NS1, NS2, or inactivated BTV-8
and corresponding control antigens. Proliferation is expressed as group means of
corrected OD (COD = ODprotein or virus − ODbackground) values after 4 days of stimulation
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espectively.
n controls 2 weeks after challenge and had increased 1 week
ater.
Increases in NS1-speciﬁc and NS2-speciﬁc serum antibody titers
ere detected in vaccinated calves 3 weeks after ﬁrst and second
accinations. Antibody titers to NS2 were signiﬁcantly higher than
hose detected in controls 3 weeks after ﬁrst vaccination (p ≤ 0.01)
nd to NS1 and NS2 3 weeks after second vaccination (p ≤ 0.05 and
 ≤ 0.01, respectively) (Fig. 4C and D). Antibodies to NS1 and NS2
BTV-2) were observed 3 weeks after BTV-8 challenge in the sera
f controls and vaccinated calves, but did not differ signiﬁcantly
p = 0.94 and p = 0.23, respectively).
.4. Detection of protein- and BTV-8-speciﬁc lymphocyte
roliferative responses
In vitro NS1-speciﬁc and NS2-speciﬁc lymphoproliferative
esponses were detected in PBMC of vaccinated calves (means:
.04 ± 0.06 and 0.05 ± 0.02 COD, respectively) 3 weeks after sec-
nd vaccination, at statistically higher levels than controls (means:
.00 ± 0.01 and 0.02 ± 0.04 COD, respectively; p ≤ 0.05 for both)
Fig. 5). Furthermore, BTV-8 speciﬁc lymphoproliferation was
etected in vaccinated calves (mean: 0.04 ± 0.04 COD) at this time
oint but not in any controls (mean: 0.00 ± 0.00 COD, p ≤ 0.01). No
P2-speciﬁc lymphoproliferatives responses were observed.
.5. Assessment of DIVA compliancy by VP7 antibody detection
VP7-speciﬁc serum antibodies were not detected in any calf
efore challenge, but were detected at high levels (≥75%) in 5/6
ontrols 2 weeks after challenge and in all controls 1 week later
mean: 92 ± 3%) (Fig. 6). Vaccinated calves also developed VP7-
peciﬁc serum antibodies following challenge, but antibody levels
emained signiﬁcantly lower than those in controls (peak mean:
4 ± 22% at 2 weeks after challenge, p ≤ 0.01).
. DiscussionIn this study, we demonstrated that the experimental vaccine
ased on VP2 of BTV-8 combined with NS1 and NS2 of BTV-2 and
n ISCOM–matrix adjuvant provided strong clinical and virolog-
cal protection against virulent BTV-8 challenge in calves. This2 (2014) 6614–6621
protection was mediated by speciﬁc immune responses directed
against all or certain proteins included in this vaccine, in agreement
with our previous ﬁndings [26]. Furthermore, the potential of the
DIVA characteristic based on VP7 was  conﬁrmed.
The clinical signs and viremia observed in controls were com-
parable to those observed in natural or experimental infections in
ruminants [30,36,37] and consequently show the efﬁcacy of SubV
in preventing both clinical and virological disease. In contrast to
previously reported challenge studies where no clinical signs were
observed [32,38], here, clinical signs including fever and some con-
gestion or mucosal edema were demonstrated in controls, but not
vaccinated calves, from 2 to 14 days post-infection. This could be
explained by passage of the challenge virus in KC cells, which may
better mimic  natural infection via Culicoides compared to virus pas-
saged in other cell cultures [39,40] as observed previously [41].
Furthermore, BTV was  only detected in the blood of controls. The
very limited clinical signs observed in three vaccinated animals
were probably unrelated to BTV since we  did not detect any viremia
in these animals by RT-qPCR analyses nor by isolation in ECE.
The strong protection observed in the vaccinated calves cor-
responds with diverse humoral and cellular immune responses
induced by SubV. Importantly, BTV-8-neutralizing antibodies were
detected in sera of vaccinated calves as soon as 1 week after sec-
ond vaccination. These antibodies were likely directed against VP2
since it is the only protein included in the experimental vaccine
known to induce them [16,19] and because the presence of VP2
antibodies was also conﬁrmed by cELISA. Our results support recent
suggestions that VP2 alone induces sufﬁcient neutralizing antibody
titers, without the aid of VP5 [42,43]. Additionally, SubV induced
speciﬁc antibody production to NS1 and NS2 following vaccination.
Although the protective contribution of cellular immune responses
against the non-structural proteins has previously been indicated
for both BTV and the related African horse sickness virus [44,45], the
role that these antibodies may  play against BTV infection remains
to be evaluated.
Low but speciﬁc T cell responses against NS1 and NS2 were
observed 3 weeks after second vaccination, which conﬁrms pre-
vious ﬁndings for NS1 and adds new information about NS2.
Compared to previously [26], the NS2-speciﬁc lymphoproliferative
responses were detected by increasing the concentration of this
protein for PBMC restimulation. NS1 and NS2 have been reported
to induce cross-serotype helper T cell [44] and cytotoxic T cell
responses [21,44,46,47]. Here, helper T cell proliferation was  likely
induced by the killed antigens used for in vitro restimulations, while
in vivo cross-presentation may have facilitated possible induction
of cytotoxic T cell responses. The ISCOM–matrix adjuvant included
in the vaccine has also been demonstrated to induce T cell responses
in cattle [34] and cross-priming leading to cytotoxic T cell responses
[48]. Since T cell responses were only detected against NS1 and
NS2 (BTV-2), but not VP2 (BTV-8), the observed lymphocyte pro-
liferation to UV-inactivated BTV-8 in vitro suggests cross-serotype
reactions induced by the NS proteins, although responses induced
by VP2, but not detected in peripheral circulation by the VP2-
speciﬁc assay employed herein, cannot be excluded. Furthermore,
species differences in T cell responses to the same protein, such as
VP2-speciﬁc lymphoproliferation observed following vaccination
in mice but not cattle [24], highlights the importance of perform-
ing vaccine studies in the target species. Speciﬁc T cell responses
from samples collected on PID7 could not be determined because
of poor viability, likely due to storage of this batch of cells in liquid
nitrogen (data not shown).
Taken together, the vaccine-induced protection was  probably
due to serotype-speciﬁc neutralizing antibodies against VP2 and
cross-serotype immune responses to NS1 and NS2. Even though
the roles of NS1 and NS2 in protection need further investigation,
we believe that the diverse immune responses induced by the
J. Anderson et al. / Vaccine 32 (2014) 6614–6621 6619
Fig. 6. Kinetics of BTV VP7- and VP2-speciﬁc serum antibodies for DIVA compliancy of SubV following BTV-8 infection. Calves were vaccinated (black arrows) with SubV (white
diamonds) or Control (black squares) and challenged with BTV-8 (white arrow), as indicated in Fig. 1. VP7-speciﬁc antibodies were detected by cELISA and mean percentages
(100%-competition percentage) for VP7 antibodies are presented in (A) with standard deviations indicated by deﬂection lines and statistical signiﬁcance between groups
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TV-8 VP2-speciﬁc antibodies (≥30%) or have high levels of VP7-speciﬁc antibodies
ixture of BTV proteins included in SubV may  contribute to its
fﬁcacy against different BTV-8 strains and perhaps to a long
uration of immunity, by potentially stimulating a broader pool
f memory B and T cells and long-lived plasma cells. This would
ave to be investigated since it has direct consequences on vaccine
se in livestock such as cattle, which have a long economical life
ompared to shorter-lived agricultural animals such as swine and
oultry. It is notable that compared to the preceding study [26],
e decreased the adjuvant quantity in SubV by 25% and observed
ess systemic and local reactions following vaccination, yet still
bserved similar immunological responses.
The DIVA characteristic of SubV is based on the detection of VP2
ntibodies, to prove serotype-speciﬁc infection or vaccination, and
ifferences in VP7 antibody levels, to distinguish between infection
nd vaccination with any serotype. VP7 has been shown to induce
ood immune responses that do not seem to be essential for protec-
ion [16,43,49] and therefore is a good DIVA candidate. All calves
ere BTV-8 seropositive within 3 weeks following BTV-8 vacci-
ation or infection. Furthermore, following BTV-8 challenge, high
P7-speciﬁc antibody levels were rapidly detected in the sera of all
ontrols. VP7 antibodies were also detected in vaccinated calves,
ut at lower levels than controls and therefore the vaccinated
nd unvaccinated animals could be distinguished. Since no virus
eplication was detected in vaccinated calves, we  believe that the
bserved antibody induction was due to the quantity of VP7 antigentibodies are presented in (B). Gray boxes indicate samples that are seropositive for
y BTV serotype (≥75%), indicating BTV replication.
present in the challenge virus, as has already been observed with
the use of a commercial inactivated vaccine [26,50], or to limited
local replication at the injection site. Based on this data, a cut-off
of ≥75% can be deﬁned to suggest BTV replication and to identify
animals in which the virus can replicate sufﬁciently to transmit,
as soon as 2–3 weeks after infection. This cut-off would probably
be lower under ﬁeld conditions. Our results indicate that SubV is
potentially DIVA compliant under these conditions but would need
to be validated with samples from naturally infected animals.
In conclusion, an experimental BTV vaccine consisting of VP2,
NS1, and NS2 induced diverse immune response and is a promis-
ing candidate vaccine that provides strong clinical and virological
protection against experimental BTV-8 infection in cattle. Further
investigations of SubV should be performed, including exchanging
or combining VP2 of other serotypes to test the vaccine’s adapt-
able nature and evaluating the duration of immunity. The DIVA
compliancy of this vaccine should also be evaluated under ﬁeld
conditions.
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